International Journal of Scientific Research and Engineering Development-– Volume 8 Issue 4, July-Aug 2025
Available at www.ijsred.com

RESEARCH ARTICLE OPEN ACCESS

A Review on A1 Assisted Spectral Finger Printing Device and Its Rapid Detections Cancer Biomarkers in Saliva Region Aspects

*Averineni Ravi Kumar, **Shaik Gowsiya Sadika, **Farhana Khatija, **Samreen Shaik, **Sayyad Shabana, **Md.Niwazunnisa
* Post Graduate Head of Department, Entrepreneurship Development Cell Cordinator , Nimra College of Pharmacy Vijayawada 521456 AP INDIA
** B Pharmacy Student, Nimra College of Pharmacy Vijayawada 521456 AP INDIA
karavi315@gmail.com

Abstract:

The use of **AI-powered spectral fingerprinting** in combination with **saliva-based diagnostics** represents a significant advancement in the early detection of cancer. By leveraging cutting-edge spectroscopic techniques such as **Raman and infrared (IR) spectroscopy**, along with machine learning algorithms, this approach can accurately identify critical cancer-related biomarkers—including **miRNAs, cytokines, and genetic mutations**—directly from a saliva sample.The integrated **A1 module** plays a central role by performing **signal processing, pattern analysis, biomarker quantification**, and **risk assessment**—delivering reliable diagnostic results within minutes. Its compact, portable design makes it ideal for **remote or underserved regions**, offering a practical solution for **early screening and personalized healthcare**.In summary, the A1-assisted salivary spectral fingerprinting system provides a **non-invasive, efficient, and cost-effective diagnostic tool**. It holds great promise for **enhancing early detection, improving treatment outcomes**, and enabling the future of **real-time, point-of-care cancer diagnostics**.

Keywords: A1 Powered Spectral, Screening health care, Biomarkers, Cancer Diagnostics.

INTRODUCTION

What is Spectroscopy?

Spectroscopy is a powerful analytical technique that studies how electromagnetic radiation interacts with matter. By observing how substances absorb, emit, or scatter light, spectroscopy enables the identification and characterization of their **molecular structure**, **composition**, and **chemical behavior**.

AI-Enhanced Spectroscopy: Common Types and Their Functions

Spectroscopy Type	Operating Principle	Key Applications
Raman Spectroscopy	Measures inelastic scattering of monochromatic light	Molecular identification, cancer diagnostics
Infrared (IR)	Analyzes absorption of infrared radiation due to vibrations	Organic compound analysis, tissue examination
UV-Visible (UV-Vis)	Measures light absorbance in the ultraviolet and visible ranges	DNA/protein quantification, drug development
Fluorescence	Detects emitted light from excited molecules	Cell imaging, biomarker tracking
NMR/Mass Spectrometry	Examines atomic nuclei or mass-to-charge ratio of particles	Structural analysis, metabolite profiling



Infrared Spectroscopy

Integration of Artificial Intelligence in Spectroscopy

AI significantly boosts the capabilities of spectroscopy by automating **data interpretation**, enhancing **accuracy**, and enabling **real-time diagnostics**.

1. Preprocessing of Spectral Data

- AI algorithms process raw spectral outputs by **eliminating noise**, **correcting baselines**, and **removing background interference**.
- Common techniques include:
  - **Savitzky-Golay filters**
  - **Principal Component Analysis (PCA)** for dimensionality reduction

2. Feature Extraction

- AI pinpoints **critical spectral features** (e.g., characteristic peaks like amide I at ~1658 cm^{-1} in Raman spectra).
- Algorithms such as:
  - **t-SNE** (for complex data visualization)
  - **Wavelet transforms** (for time-frequency feature analysis)



3. Classification & Pattern Recognition

- Spectral datasets are fed into AI models that classify:

  - **Healthy vs. Diseased**
  - **Type or stage of cancer**
- Common models:
  - **Support Vector Machines (SVM)**
  - **Random Forest**
  - **Convolutional Neural Networks (CNNs)**
  - **Deep Neural Networks (DNNs)**

4. Quantitative Spectral Analysis

- AI can estimate **concentrations of biomarkers** (e.g., miRNA, proteins) within a sample.
- Regression-based models used:
  - **Partial Least Squares Regression (PLSR)**
  - **Deep Regression Networks**

5. Outlier Detection and Novelty Identification

- AI detects **unusual or unknown patterns** in spectral data.
- Useful for identifying **early-stage disease markers** or **emerging biomolecular signatures**.

Biomedical Applications: AI + Spectroscopy in Disease Detection

Use Case	Spectroscopy Method	AI Contribution
Oral Cancer	Raman, IR	Detects protein/lipid abnormalities in saliva
Breast Cancer (miRNA)	Raman, UV-Vis	Analyzes miRNA-related spectral shifts
Lung Cancer (EGFR)	IR, Mass Spectrometry	Recognizes mutated protein patterns
Prostate Cancer	Raman, NMR	Classifies prostate-specific antigen spectra



Common AI Techniques Used in Spectroscopic Analysis

Approach	Example Algorithms	Purpose
Supervised Learning	SVM, Random Forest, k-Nearest Neighbors	Label-based classification and prediction
Unsupervised Learning	PCA, k-Means, Hierarchical Clustering	Exploratory data grouping and visualization
Deep Learning	CNNs, RNNs, Autoencoders	End-to-end feature extraction and classification
Transfer Learning	Adapted pretrained models	Application across related domains or sample types
Reinforcement Learning	Real-time adaptive models	Optimizes scanning and decision-making on-the-fly

Example Workflow: AI + Raman Spectroscopy for Cancer Screening

1. **Saliva Sample Collection**
    - A quick and painless procedure to obtain biological material.
2. **Spectral Data Acquisition**
    - Raman spectrometer captures high-resolution molecular fingerprints.
3. **Preprocessing & Cleaning**
    - AI algorithms remove noise and normalize the spectrum.
4. **Pattern Recognition via CNN**
    - Deep learning model identifies cancer-associated spectral patterns.
5. **Result Generation**
    - AI delivers a diagnostic report (e.g., "High Probability: Oral Cancer").



CANCER SCREENING

Advantages of AI-Driven Spectroscopy in Healthcare



- **Rapid diagnostics**: Results within minutes instead of days
- **Improved accuracy**: Reduces diagnostic errors and variability
- **Non-invasive**: Uses saliva, urine, or breath instead of blood or biopsies
- **Early detection**: Identifies disease before clinical symptoms appear

Scalable solutions: Ideal for remote or resource-limited settings

Emerging Trends and Future Potential

Innovation Area	Description
Edge AI Integration	Enables local processing on handheld or portable devices
Explainable AI (XAI)	Makes AI predictions more transparent and clinically interpretable
Hybrid Spectral Models	Combines data from Raman, IR, and UV-Vis for enhanced diagnostic precision
Real-Time Drug Monitoring	Uses AI to track therapeutic response via live spectral analysis

What is A1-Assisted Spectral Fingerprinting?

A1-Assisted Spectral Fingerprinting refers to a cutting-edge diagnostic approach that merges **Artificial Intelligence (AI)** with **advanced spectroscopy techniques**—such as Raman, Infrared (IR), and UV-Vis spectroscopy—to detect specific molecular "fingerprints" of cancer biomarkers within complex biological fluids like **saliva**. These fingerprints are unique spectral patterns that correspond to molecular compositions associated with various cancers.


botanical/animal origin
geographical origin
rearing system
production year
freshness level
production technology
...
Classification with respect to label attributes
undeclared substance addition
partial or total substitution
mixtures
Adulteration detection
fruit juices
dairy products
oil
honey
meat
Artificial Intelligence in food authentication
Quality assessment based on image processing
hyperspectral images
3D fluorescence spectra
microscope images
thermal images
digital images


Raman Scattering
Fiber optic from laser source
Rd Diffuse reflectance
Fluorescence
Scatterer
μ_s
μ_a
ϑ
g=<cos(ϑ)>
STUDIED SAMPLE
Absorber
Fluorophore
Td

Core Components and Functional Workflow

Component	Description
Spectroscopy Module	Captures optical signatures (absorption, scattering, or emission spectra) from the saliva sample.
Saliva Input System	A non-invasive, user-friendly collection interface for acquiring saliva samples.
A1 AI Engine	A trained machine learning model that analyzes spectral data to detect abnormalities.
Biomarker Repository	A reference database housing known spectral profiles of various cancer biomarkers.
User Dashboard	Displays diagnostic results, risk assessments, and potential cancer type indicators.

Key Salivary Cancer Biomarkers

Biomarker	Cancer Type	Presence in Saliva Explained
p53 Antibodies	Oral, Head & Neck	Released during cell apoptosis, detectable in oral fluids.
EGFR	Lung, Breast, Oral	Epithelial shedding leads to its presence in saliva.
miR-21 (miRNA)	Breast, Pancreatic, Prostate	Stable in saliva, reflects changes in gene expression.
CA-125	Ovarian	Diffuses into saliva via salivary gland transudation.
IL-6, IL-8	Tumor Microenvironment	Elevated in both oral and systemic cancers.

What Are Salivary Cancer Biomarkers?

Salivary cancer biomarkers are **biological molecules found in saliva** that serve as indicators of cancer presence, progression, or type. These markers either come directly from tumor cells or are produced as part of the body's response to cancer. They enter saliva through several physiological processes:

- **Blood-derived diffusion (transudation)**
- **Local secretion from oral tumors**
- **Epithelial cell shedding**
- **Release of extracellular vesicles (e.g., exosomes)**

These biomarkers can take the form of **proteins, nucleic acids (DNA/RNA), cytokines, metabolites**, or **autoantibodies**.

Classification of Salivary Biomarkers by Molecular Type

Biomarker Type	Examples	Diagnostic Significance
Proteins	EGFR, CA15-3, CA-125, HER2, CYFRA 21-1	Reflect tumor growth, proliferation, or overexpression in cancer cells
mRNA Transcripts	IL-8 mRNA, DUSP1, S100P, SAT1	Show gene expression changes specific to tumors

Biomarker Type	Examples	Diagnostic Significance
microRNAs (miRNAs)	miR-21, miR-125a, miR-200a, miR-31	Regulate cancer genes; remain stable in saliva; highly cancer-specific
Cytokines	IL-6, IL-8, TNF-α	Indicate inflammation and immune responses related to tumors
Genetic Mutations	p53, KRAS, HPV DNA	Somatic mutations or viral oncogenes tied to tumor development
Autoantibodies	Anti-p53 antibodies	Immune markers generated against mutated tumor suppressor proteins
Metabolites	Tyrosine, Polyamines	Reflect altered metabolism in cancer cells (Warburg effect, etc.)



Salivary Cancer Biomarkers

How Do Biomarkers Reach the Saliva?

- **Transcellular Transport**: Molecules diffuse or are actively transported across salivary gland cells from the bloodstream.
- **Paracellular Movement**: Biomarkers pass between epithelial cells, often during inflammation or barrier damage.
- **Gingival Crevicular Fluid (GCF)**: A fluid between the gum and teeth that carries immune markers and proteins from the blood into the mouth.

- **Exosome and Vesicle Release**: Tumor-derived exosomes containing RNA, proteins, and DNA are released into saliva.

Cancers with Detectable Salivary Biomarkers

Oral Squamous Cell Carcinoma (OSCC)

Biomarker	Type	Diagnostic Role
IL-8, IL-1β	Cytokines	Indicate inflammation and tumor-supportive microenvironment
S100P, DUSP1	mRNA	Upregulated in oral cancer cells
miR-31	microRNA	Commonly elevated in saliva of OSCC patients
Anti-p53 Antibodies	Autoantibodies	Reflect p53 mutations frequently seen in OSCC

Breast Cancer

Biomarker	Type	Function
HER2, CA15-3	Proteins	Indicate tumor presence or aggressive phenotype
miR-21, miR-125a	microRNAs	Linked to cancer progression and chemoresistance
p53 mRNA	RNA	Suggests mutations related to genomic instability



Lung Cancer

Biomarker	Type	Function
EGFR	Protein	Often mutated in non-small cell lung cancer (NSCLC)
CYFRA 21-1	Protein	Cytokeratin fragment elevated in cancer patients
miR-205	microRNA	Upregulated in lung adenocarcinoma



Pancreatic Cancer

Biomarker	Type	Function
miR-21, miR-200a	microRNAs	Involved in epithelial-mesenchymal transition (EMT) and metastasis
MUC1	Protein	Overexpressed in pancreatic tumors
KRAS Mutations	DNA	Early genetic changes in pancreatic malignancy



Prostate Cancer

Biomarker	Type	Function
PSA (Prostate Antigen)	Protein	Often leaks from blood into saliva in cancer cases
miR-141, miR-375	microRNAs	Significantly elevated in advanced disease



Prostate Cancer

Why Use Salivary Biomarkers? Key Advantages

Benefit	Explanation
Non-Invasive Sampling	Easily collected without the need for blood draws or surgical biopsies
Low Cost	Requires minimal laboratory equipment and handling
Painless & Safe	Suitable for frequent monitoring or population-wide screenings
Real-Time Monitoring	Tracks response to treatment or disease progression efficiently
Local & Systemic Insight	Detects both oral and distant cancer types through salivary analysis

Clinical Applications of Salivary Biomarkers

Use Case	Purpose
Early Detection	Identifies cancer before symptoms become evident
Treatment Monitoring	Tracks biomarker fluctuations to gauge therapy effectiveness
Surveillance After Therapy	Detects recurrence or residual disease after treatment
Risk Stratification	Helps distinguish between malignant and benign conditions
Precision Medicine	Aids in selecting targeted therapies based on biomarker profiles

Emerging Technologies for Salivary Biomarker Detection

- 🔍 **AI-Powered Spectroscopy**: Uses Raman or IR spectroscopy with AI for fast, label-free detection.
- 🧪 **Lab-on-a-Chip Platforms**: Miniaturized diagnostic devices for multi-biomarker saliva testing.
- ⚡ **Electrochemical Biosensors**: Portable tools that measure DNA, RNA, or proteins using current changes.
- 🧬 **Next-Generation Sequencing (NGS)**: Allows ultra-sensitive analysis of exosomal RNA or tumor-derived DNA in saliva.



AI (A1) Module Capabilities

The "A1" engine operates as a smart diagnostic assistant using:

- **Supervised Machine Learning**: Trained with large datasets of both healthy and diseased spectral data.
- **Pattern Recognition**: Identifies and matches biomarker-specific spectral patterns.
- **Outlier Detection**: Flags spectral signals that deviate from the normal range.
- **Risk Scoring System**: Provides a probabilistic risk index indicating the likelihood of cancer presence.

Example: If specific spectral features associated with miR-21 and IL-8 are detected, the A1 module may flag a high probability of **oral squamous cell carcinoma**.



What is the A1 Module?

The **A1 Module** serves as the intelligent core of an AI-assisted spectral fingerprinting system. It is designed to process and interpret complex spectral data—particularly from non-invasive biological samples like saliva—to detect and quantify cancer-related biomarkers in real-time.

Using advanced **machine learning, statistical analysis, and decision-making algorithms**, the A1 module transforms raw spectral inputs into actionable diagnostic insights.

Core Functionalities of the A1 Module

Functionality	Purpose
Signal Preprocessing	Cleans and formats raw spectral input for reliable interpretation
Feature Identification	Detects key spectral indicators linked to cancer biomarkers
Pattern Analysis	Compares detected patterns with established cancer fingerprint databases
Diagnostic Classification	Labels the input sample as normal, abnormal, or cancer-positive
Biomarker Quantification	Estimates concentrations of specific biomarkers (e.g., miR-21, IL-8)
Outlier Detection	Flags unknown or rare spectral signatures for further investigation
Risk Prediction	Provides a personalized cancer probability score
Model Updating	Learns from new data over time to improve accuracy and adaptability

1. Signal Preprocessing Techniques

Before analysis, the raw spectral data—often noisy or distorted—undergoes optimization:

- **Noise Elimination**: Filters out background and instrument noise using methods like Savitzky-Golay smoothing.
- **Baseline Adjustment**: Corrects for any baseline shift caused by sample fluorescence.
- **Normalization**: Standardizes intensity values for consistency (e.g., z-score, min-max scaling).

Common Algorithms:

- Principal Component Analysis (PCA)
- Wavelet Transform
- Fourier Filtering
- Moving Average Filters

2. Biomarker Feature Extraction

The module identifies relevant **vibrational peaks and spectral regions** that indicate the presence of specific cancer biomarkers.

Techniques Include:

- Peak detection and labeling
- Spectral curve fitting
- Correlation-based tagging
- Biomarker-specific scoring (e.g., for miR-21, tyrosine, EGFR)

3. Pattern Recognition in Spectral Data

Using AI models trained on known datasets, A1 analyzes spectral patterns for disease signatures.

Machine Learning Methods:



- Support Vector Machines (SVM)
- Random Forest classifiers
- k-Nearest Neighbors (k-NN)

- Convolutional Neural Networks (CNNs) for one-dimensional spectral inputs

Training Data Includes:

- Spectra from healthy individuals
- Saliva spectra from patients with confirmed cancer diagnoses (various stages and types)

4. Diagnostic Classification

The module categorizes each sample into one of several diagnostic groups:

- **Healthy / Normal**
- **Early-stage Cancer**
- **Late-stage / Advanced Cancer**
- **Inconclusive – Refer for further testing**

Each result is paired with a **confidence level** (e.g., 92% certainty for OSCC).

Classifiers Used:

- Multi-class models
- Ensemble learning algorithms
- Feedforward Neural Networks

5. Quantitative Biomarker Measurement

The A1 module doesn't just detect biomarker presence—it can estimate **concentration levels**, which is valuable for monitoring disease progression or treatment response.

Regression Techniques:

- Partial Least Squares Regression (PLSR)
- Deep Regression Neural Networks
- Gradient Boosting Models (e.g., XGBoost)

6. Detection of Outliers and Anomalies

The system is trained to recognize and flag spectral data that don't match any known patterns, which could indicate:

- A rare form of cancer
- An emerging biomarker signature
- Sample contamination or variability

Methods Applied:

- Autoencoders (for reconstruction error)
- One-Class SVM
- Isolation Forests

7. Predictive Cancer Risk Assessment

A1 generates **personalized cancer risk scores** by evaluating:

- Biomarker intensity levels
- Presence of multiple biomarkers
- Patient metadata (age, sex, clinical history) if integrated

Example Output Ranges:

- **Low Risk**: 0–25%
- **Medium Risk**: 26–70%
- **High Risk**: 71–100%

8. Self-Learning and Model Evolution

If the system is connected to the cloud or designed with edge learning capabilities, it can:

- Retrain using new patient samples
- Adapt to newly discovered biomarkers
- Enable **federated learning**, preserving privacy while sharing learning across devices or hospitals

9. Clinical Dashboard and Reporting

The A1 module is equipped with a **user interface** that:

- Visualizes real-time biomarker levels
- Shows diagnostic status and risk trends
- Exports results to electronic health records (EHRs) or patient apps
- Provides printable and sharable reports for doctors and patients

Real-World Use Case Example

Scenario: A patient provides a saliva sample for cancer screening.

1. The device acquires the spectral data using Raman or IR spectroscopy
2. A1 preprocesses the signal and extracts features
3. It identifies **miR-31, IL-8**, and elevated **tyrosine** spectral signatures
4. Based on pattern matching and scoring, A1 classifies it as "**High Risk: Early Oral Cancer**"
5. A diagnostic report is generated and displayed within **5 minutes**

Advantages of the A1 Module in Medical Diagnostics

Advantage	Explanation
Rapid Diagnosis	Delivers results in real time—ideal for clinics and remote screening
High Sensitivity	AI reduces false positives/negatives by learning from complex datasets
Scalable	Can be embedded in handheld devices or large lab equipment
Customizable	Learns from local population data to improve relevance and accuracy

Advantage	Explanation
Offline Capability	Can operate without internet access in low-resource environments

Why Saliva is an Ideal Diagnostic Medium

Advantage	Explanation
Non-Invasive	Eliminates the need for needles or surgical tissue sampling.
Affordable	Low-cost collection, storage, and processing.
Rapid Screening	Suitable for real-time diagnostics at the point of care or home use.
Systemic Relevance	Reflects biomarkers from both local (oral) and distant (systemic) tumors.



System Design and Implementation Overview

Hardware Infrastructure:

- **Compact Spectrometer**: Ensures portability for bedside or field use.
- **Disposable Collection Kit**: Ensures hygiene and sample integrity.
- **Optical Detectors**: Tuned for high sensitivity to molecular vibrations.

Software Intelligence:

- Pre-trained **deep learning** or **SVM models** for biomarker detection.
- **Real-time spectral processing** on-device or via cloud infrastructure.
- Remote update and analytics via secure **cloud connectivity**.

Primary Use Cases in Oncology

Oral Cancer Detection

- **Indicators**: Altered protein signatures, tyrosine peaks
- **AI Function**: Matches against oral cancer spectral templates

Breast Cancer Detection

- **Markers**: miRNAs and CA-15-3-related spectral shifts
- **AI Response**: Uses neural network models to classify cancer risk

Lung and Pancreatic Cancer Detection

- **Markers**: EGFR, KRAS mutations detected via secondary changes in saliva
- **AI Capability**: Differentiates between benign and malignant patterns

Detection Speed and Efficiency

- **Complete Analysis Time**: Approx. **5 to 15 minutes** from sample to result.
- **AI Computation Time**: **Milliseconds**, allowing near real-time decision-making.
- Optimized for **remote clinics, emergency care**, and **mobile diagnostics**.

Advantages at a Glance

- **Fast and accurate** disease detection
- **Non-invasive** alternative to blood tests and biopsies
- **Portable** and compatible with mobile diagnostic platforms
- **AI-enabled** personalized health assessment
- **Cost-effective** for mass screening in rural or low-resource settings

Future Enhancements and Innovation Pathways

- Integration with **wearable biosensors** for continuous saliva monitoring
- Expansion into **multi-cancer detection panels** with broader biomarker coverage
- **Cloud-based AI training** for dynamic model updates and global data collaboration
- Use of **blockchain** to secure patient data and enhance traceability of diagnoses

CONCLUSION

A1-Assisted Spectral Fingerprinting Device for Rapid Salivary Cancer Biomarker Detection

1. Integration

The A1-Assisted Spectral Fingerprinting Device combines Artificial Intelligence (A1 module) with advanced spectral data acquisition techniques. This integration enables precise, real-time analysis of saliva samples for cancer biomarker detection.

Key Components:

- Spectral Sensor: Captures molecular spectral data.
- Saliva Collection Unit: Facilitates non-invasive, hygienic sample collection.
- AI Analytical Engine (A1 Module): Processes and interprets spectral data.
- User Interface: Provides diagnostic results and reports.

Core Functionality:

- Real-time data preprocessing and noise reduction.
- Feature extraction highlighting key biomarker signatures.
- Pattern recognition for cancer-specific spectral fingerprints.
- Risk scoring for assessing cancer likelihood.

2. Salivary Cancer Biomarkers Detectable

The device identifies various molecular biomarkers present in saliva, including:

- **Proteins:** EGFR, CA15-3, CA-125, HER2, among others.
- **Nucleic Acids:** microRNAs (e.g., miR-21), mRNAs, and DNA mutations such as p53 and KRAS.
- **Cytokines:** IL-6, IL-8, which indicate inflammatory responses.
- **Autoantibodies** and metabolic molecules.

These biomarkers correlate with several cancer types such as oral, breast, lung, pancreatic, and prostate cancers.

3. Technical Capabilities of the A1 Module

The A1 module delivers advanced analytical functions including:

- Noise filtering and normalization of raw spectral data.
- Machine learning algorithms for classifying cancer presence and quantifying biomarkers.
- Anomaly detection to flag unusual or unknown spectral patterns.
- Predictive scoring to estimate cancer risk levels.
- Continuous learning via cloud or edge computing for model updates and improved accuracy.

4. Applications and Benefits

- Enables rapid, point-of-care screening and early cancer detection.

- Portable and user-friendly design supports use in remote or resource-limited environments.
- Personalized diagnostic outputs facilitate targeted patient management.
- Reduces the need for invasive biopsies and lowers overall healthcare costs.

5. Challenges to Address

- Maintaining high specificity and sensitivity across diverse patient populations.
- Seamlessly integrating with existing clinical workflows and healthcare systems.
- Ensuring data privacy and security, especially with cloud-based data handling.
- Meeting regulatory requirements and obtaining clinical validation for widespread adoption.

6. Future Perspectives

1. Advanced AI and Multi-Modal Integration

- Combining spectral data with complementary biosignals such as imaging and genomic data.
- Leveraging deep learning and transfer learning techniques to enhance diagnostic accuracy.

2. Wearable and Continuous Monitoring

- Development of wearable biosensors that incorporate spectral fingerprinting for ongoing cancer biomarker tracking.

3. Expanded Biomarker Panels

- Including broader panels to detect multiple cancer types simultaneously for comprehensive screening.

4. Cloud-Based Collaborative Platforms

- Implementing federated learning approaches to facilitate privacy-preserving data sharing across institutions.

5. Personalized Medicine and Therapy Monitoring

- Integrating diagnostics with personalized treatment plans to monitor therapy response and disease progression dynamically.

6. Regulatory and Commercial Deployment

- Streamlining clinical trials and regulatory approval processes.
- Scaling manufacturing for broad adoption in clinical and home-care settings.

AKNOWLEDGEMENTS : The authors are thankful to all those who guided to write this useful article and International Patent apply it Proposals of this topic related.

REFERENCES

1. López-López, E., Tomás, V., & Segura-Carretero, A. (2020). This study reviews the application of artificial intelligence and machine learning methods in Raman spectroscopy for diagnosing diseases,

highlighting advancements in analytical chemistry. *Trends in Analytical Chemistry*, 124, 115790. https://doi.org/10.1016/j.trac.2020.115790

2.Zhang, L., Xiao, H., & Wong, D. T. W. (2012). A comprehensive overview of salivary biomarkers and their potential clinical uses, focusing on molecular diagnosis and therapeutic monitoring. *Molecular Diagnosis & Therapy*, 16(4), 217–228. https://doi.org/10.1007/s40291-012-0003-3

3. Sahu, S. S., Yadav, S., & Singh, R. (2021). Exploration of artificial intelligence applications in spectroscopy for cancer detection, including future trends and technological challenges. *Computers in Biology and Medicine*, 129, 104139. https://doi.org/10.1016/j.compbiomed.2020.104139

4.Zhang, A., Sun, H., Yan, G., Wang, P., & Wang, X. (2016). Discusses the role of saliva metabolomics in biomarker discovery, disease diagnosis, and therapeutic strategies. *Applied Biochemistry and Biotechnology*, 178(4), 674–684. https://doi.org/10.1007/s12010-015-1960-3

5.Subhash, H., & Kandpal, M. (2019). Presents Raman spectroscopy combined with machine learning as an effective approach for cancer diagnosis utilizing saliva samples. *Biosensors*, 9(3), 82. https://doi.org/10.3390/bios9030082

6. Hu, S., Arellano-Garcia, M. E., Wang, J., Ogorzalek Loo, R. R., Loo, J. A., & Wong, D. T. (2008). Investigation of salivary proteomics aimed at identifying biomarkers for oral cancer detection. *Clinical Cancer Research*, 14(19), 6246–6252. https://doi.org/10.1158/1078-0432.CCR-08-0520

7.Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., et al. (2005). MicroRNA expression profiling as a method to classify human cancers. *Nature*, 435(7043), 834–838. https://doi.org/10.1038/nature03702

8. Rosenberg, A. E., & Pavlidakey, P. (2021). Advances in point-of-care spectroscopy technologies for cancer diagnosis with emphasis on analytical chemistry developments. *Annual Review of Analytical Chemistry*, 14, 179–199. https://doi.org/10.1146/annurev-anchem-091620-094638

9. Wang, K., Yuan, Y., Cho, J. H., McClarty, S. M., Baxter, D., & Galas, D. J. (2012). Comparative analysis of microRNA profiles in serum and plasma samples. *PLoS ONE*, 7(7), e41561. https://doi.org/10.1371/journal.pone.0041561

10.Yadav, S., & Kumar, A. (2023). Review of AI-enhanced multi-modal spectroscopy techniques for early cancer detection including current applications and future prospects. *Sensors and Actuators B: Chemical*, 367, 132054. https://doi.org/10.1016/j.snb.2023.132054

11.Han C et al. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecol. Oncol 149, 585–591 (2018).

12.Yu K-H et al. Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features. Nat. Commun 7, 12474 (2016).

13.Moore LE et al. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 118, 91–100 (2012).

14.“Raman Spectroscopy of Proteins: A Review”, A. Rygula, K. Majzner, K. M. Marzec, A. Kaczor, M. Pilarczyk and M. Baranska, Journal of Raman Spectroscopy, 2013, 44, 1061 – 1076.
15.“Raman Spectroscopy of Protein Pharmaceuticals”, Zai-Qing Wen, Journal of Pharmaceutical Sciences, Vol. 96, No. 11, November 2007, pp 2861- 2878.

16.Hofmarcher T, Lindgren P, Wilking N, Jönsson B. The cost of cancer in Europe 2018. European. J Cancer. 2020;129:41–9.

17.Harrison CJ, Spencer RG, Shackley DC. Transforming cancer outcomes in England: earlier and faster diagnoses, pathways to success, and empowering alliances. J Healthc Leadersh. 2019;11:1–11.

18.Banegas MP, Yabroff KR, O’Keeffe-Rosetti MC, Ritzwoller DP, Fishman PA, Salloum RG, et al. Medical care costs associated with cancer in integrated delivery systems. J Natl Compr Cancer Netw. 2018;16:402–10.

19.Dolly SO, Jones G, Allchorne P, (2021) The effectiveness of the Guy’s Rapid Diagnostic Clinic (RDC) in detecting cancer and serious conditions in vague symptom patients. *Br J Cancer* **124**, 6, 1079–1087

20.Cross, A.J., Moore, S.C., Boca, S., et al., 2014. A prospective study of serum metabolites and colorectal cancer risk. Cancer 120 (19), 3049–3057

21.Surface-Enhanced Raman Spectroscopy: Bioanalytical, Biomolecular and Medical Applications By Marek Procházka (Springer, 2016)

